Edition:
India

OPKO Health Inc (OPK.OQ)

OPK.OQ on NASDAQ Stock Exchange Global Select Market

4.98USD
15 Dec 2017
Change (% chg)

$0.13 (+2.68%)
Prev Close
$4.85
Open
$4.90
Day's High
$5.00
Day's Low
$4.83
Volume
3,213,168
Avg. Vol
1,036,931
52-wk High
$12.15
52-wk Low
$4.50

Latest Key Developments (Source: Significant Developments)

Opko Health qtrly loss per share $0.08‍​
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Opko Health Inc ::Opko Health reports 2017 third quarter highlights and financial results.Q3 revenue $263.5 million versus I/B/E/S view $319.4 million.Opko Health Inc qtrly loss per share $0.08‍​.  Full Article

OPKO Health submits premarket approval application with FDA for PSA test
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - OPKO Health Inc :OPKO Health submits premarket approval application with FDA for a point-of-care PSA test with the Claros 1 platform.OPKO Health Inc - ‍filing contains clinical data from company's 864-patient total psa clinical study​.OPKO Health Inc - ‍OPKO expects to initiate clinical validation studies and to file a 510(k) application for a Claros 1 testosterone test in 2018​.OPKO Health - working to add additional tests for vitamin D, infectious diseases, cardiology, women's health, companion diagnostics to Claros 1 menu​.  Full Article

Xenetic Biosciences enters into sublicense agreement with subsidiary of Shire Plc
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Xenetic Biosciences :Xenetic Biosciences enters into sublicense agreement related to its Polyxen technology with Baxalta Inc., a wholly-owned subsidiary of Shire Plc.Xenetic Biosciences Inc - ‍Xenetic to receive one-time payment of $7.5 million and single digit royalty payments based upon net sales​.  Full Article

Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Opko Health Inc ::Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy.‍Tesaro is expected to launch Varubi IV in November 2017​.  Full Article

Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee in Japan
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Opko Health Inc :Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee® in Japan.Opko Health Inc - ‍Under terms of agreement, JT will make an upfront payment to Opko of $6 million.Opko Health says unit ‍eirgen Pharma entered into an exclusive agreement with Japan Tobacco for development and commercialization in Japan of Rayaldee​.Opko Health - As per agrement, co eligible to receive up to additional $31 million in development & regulatory milestones & $75 million in sales based milestones​.Opko Health Inc - JT will make​ another ‍$6 million payment to co upon initiation of Opko's planned phase 2 study of Rayaldee in U.S. dialysis patients.  Full Article

Xenetic Biosciences reports Q2 loss per share $0.34
Tuesday, 15 Aug 2017 

Aug 15 (Reuters) - Xenetic Biosciences Inc :Xenetic biosciences reports 2017 second quarter financial results and provides business update.Qtrly loss per share $0.34.  Full Article

Opko Health CEO Phillip Frost reports purchase of 9,200 shares of co's common stock
Monday, 22 May 2017 

May 22 (Reuters) - Opko Health Inc :CEO Phillip Frost reports purchase of 9,200 shares of co's common stock on May 19 - SEC filing.  Full Article

Opko Health qtrly diluted income per share $0.02
Tuesday, 9 Aug 2016 

Opko Health Inc : Opko health reports improved financial and operating results . Qtrly diluted income per share $ 0.02 .Qtrly total revenue $357.1 million versus $42.4 million.  Full Article

Opko Health says Transition Therapeutics will pay co fee of $3 mln if deal is terminated -SEC filing
Thursday, 30 Jun 2016 

Opko Health : If agreement is terminated under certain circumstances Transition Therapeutics will be required to pay co termination fee of $3 million Source: (http://1.usa.gov/29cpxUH ) Further company coverage: [OPK.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Opko Health to acquire Transition Therapeutics
Thursday, 30 Jun 2016 

Opko Health Inc : Says under terms, Transition Therapeutics security holders to receive approximately 6.4 million shares of Opko common stock . Says transaction is valued at approximately us$60 million, or us$1.55 per share of Transition Therapeutics common stock . Says deal approved by boards of directors of both companies .Opko Health to acquire Transition Therapeutics.  Full Article

BRIEF-Opko Health qtrly loss per share $0.08‍​

* Opko Health reports 2017 third quarter highlights and financial results